Dorsey Wright & Associates Buys New Position in Medpace Holdings, Inc. $MEDP

Dorsey Wright & Associates bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 9,885 shares of the company’s stock, valued at approximately $5,082,000. Medpace makes up 1.1% of Dorsey Wright & Associates’ holdings, making the stock its 27th largest holding.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quent Capital LLC bought a new position in shares of Medpace in the third quarter valued at approximately $25,000. Optiver Holding B.V. bought a new stake in Medpace during the third quarter worth approximately $27,000. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Quarry LP acquired a new stake in Medpace in the third quarter worth approximately $35,000. Finally, Employees Retirement System of Texas bought a new position in Medpace during the 2nd quarter valued at $36,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 0.3%

Shares of Medpace stock opened at $455.15 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92. The firm has a market capitalization of $12.92 billion, a PE ratio of 29.75, a price-to-earnings-growth ratio of 2.17 and a beta of 1.44. The stock’s fifty day moving average is $517.88 and its 200-day moving average is $539.13.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same period last year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on MEDP. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Leerink Partners cut their price objective on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Truist Financial lowered their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Finally, Barclays upgraded shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price target on the stock in a research report on Friday, March 6th. Five investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus target price of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.